Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...
CRISPR Therapeutics (CRSP) reported new preclinical data from its novel SyNTase gene editing platform for the treatment of Alpha-1 Antitrypsin ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...
CRISPR Therapeutics (CRSP) announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy, ESGCT, ...
-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose- CRISPR Therapeutics is advancing a pipeline of in ...
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
Late-breaking data at the ESC Congress showcased the success of STX-1200, a novel CasXE-based therapy for durably lowering Lp(a). STX-1200 achieved unprecedented potency and specificity, with >90% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback